Outsourcing in Clinical Trials New England 20147-8 October 2014, Boston, MA
Welcome to the flagship event in our global Outsourcing in Clinical Trials Series. Last year over 400 pharmaceutical, biotechnology and medical device professionals attended Outsourcing in Clinical Trials New England event to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical challenges.
With such enthusiasm around this conference, this October’s event will once again bring together the industry leaders from within this hub for two days of presentations, case studies, panel discussions and roundtables, alongside the networking opportunity. With over 50 speakers participating, the content will cover all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques.
We are pleased to announce an additional Speaker has joined the program. Rachel Morgan (Global Head, Clinical Science and Innovation, Translational Medicine, Novartis Institute Biomedical Research) will be joining David Connelly, (Chief Executive Officer, Cmed Group) for a presentation at 4pm on the first day of the event
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout Southern California.
Outsourcing in Clinical Trials New England boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
US-based biopharmaceutical firm Clearside Biomedical has started patient enrolment in a Phase II trial of its proprietary formulation of triamcinolone acetonide, CLS-TA, to treat macular edema associated with retinal vein occlusion (RVO).
Amgen and its subsidiary Onyx Pharmaceuticals have reported positive results from a Phase III head-to-head ENDEAVOR trial of Kyprolis (carfilzomib) for Injection in combination with low-dose dexamethasone versus Velcade (bortezomib) and low-dose dexa…
US-based biopharmaceutical firm Gradalis has started a Phase III registration trial for its proprietary autologous immunotherapy, Vigil, to treat women with stage III/IV ovarian cancer.
MicuRx Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) to begin Phase II clinical trial in the US for MRX-I, an oral oxazolidinone antibiotic designed to treat infections caused by Gram-positive bacteria, including…
US-based Theravance Biopharma has enrolled first patient in its Phase III registrational trial of telavancin, a once-daily dual-mechanism antibiotic, to treat Staphylococcus aureus bacteremia.
The experimental drug favipiravir could improve survival rate in Ebola patients, if administered at earlier stages of the disease, a new study by the Alliance for International Medical Action (ALIMA) has claimed.